Improving care for patients with heart failure: What can Taiwan accomplish?

Acta Cardiologica Sinica

Volumn 23, Issue 4, 2007, Pages 211-224

  Chen, Shyh Ming ^a   Chen, Mien Cheng ^a   Tang, W H Wilson ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Disease management program; Heart failure; Taiwan

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CARDIAC AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; INSULIN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LISINOPRIL; LOOP DIURETIC AGENT; METFORMIN; METOPROLOL; NITROPRUSSIDE SODIUM; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SPIRONOLACTONE; TORASEMIDE; UNINDEXED DRUG; VASODILATOR AGENT;

CARDIOPULMONARY EXERCISE TEST; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CULTURAL FACTOR; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MEGADOSE; EDEMA; EVIDENCE BASED MEDICINE; FLUID RETENTION; GENOTYPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; MORTALITY; PATIENT CARE; POPULATION RESEARCH; RACE DIFFERENCE; REVIEW; SIDE EFFECT; SURVIVAL RATE; TAIWAN; THIOCYANATE TOXICITY; UNSPECIFIED SIDE EFFECT; UREMIA;

EID: 39149108183     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the national health service in the UK. European Journal Of Heart Failure. 2002;4:361-71.
2. Macintyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66, 547 patients hospitalized between 1986 and 1995. [see comment]. Circulation. 2000;102:1126-31.
3. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. [see comment]. Archives Of Internal Medicine. 2002;162:1689-94.
4. Chen MC, Chang HW, Cheng CI, et al. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology. 2003;100:136-42.
5. Huang CM, Young MS, Wei J. Predictors of short-term outcome in chinese patients with ambulatory heart failure for heart transplantation with ejection fraction < 25%. Japanese Heart Journal. 2000;41:349-69.
6. Huang CH, Chien KL, Chen WJ, et al. Impact of heart failure and left ventricular function on long-term survival: report of a community-based cohort study in Taiwan. European Journal of Heart Failure. 2007;9:587-93.
7. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the american heart association statistics committee and stroke statistics subcommittee. [erratum appears in Circulation. 2006 Apr 11;113(14):E696]. Circulation. 2006;113:E85-151.
8. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data. Vital & Health Statistics - Series 13: Data from The National Health Survey. 2004;1-198.
9. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. [see comment]. Archives of Internal Medicine. 1997;157:99-104.
10. Lee CH. Efficiency of health care system in Taiwan. Taiwan J Public Health. 2003;22:89-96.
11. Donahue MP, Marchuk DA, Rockman HA. Redefining heart failure: the utility of genomics. [Review] [78 Refs]. J Am Coll Cardiol. 2006;48:1289-98.
12. Chiang FT, Hsu KL, Tseng CD, et al. Association of the renin gene polymorphism with essential hypertension in a Chinese population. Clinical Genetics. 1997;51:370-4.
13. Tsai CT, Fallin D, Chiang FT, et al. Angiotensinogen Gene Haplotype and Hypertension: Interaction with ACE Gene I Allele. Hypertension. 2003;41:9-15.
14. Sanderson JE, Yu CM, Young RP, et al. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. American Heart Journal. 1999;137:653-7.
15. Huang W, Xie C, Zhou H, et al. Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. European Journal Of Heart Failure. 2004;6:23-7.
16. Sanderson JE, Young RP, Yu CM, et al. Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. American Journal of Cardiology. 1996;77:1008-10.
17. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly admitted to hospital with heart failure in the United Kingdom: historical cohort study. BMJ. 2003;327:526-31.
18. Taylor AL. The African American Heart Failure Trial: A clinical trial update. [Review] [26 Refs]. American Journal of Cardiology. 2005;96:44-8.
19. Chen YC. Chinese values, health and nursing. [Review] [20 refs]. Journal of Advanced Nursing. 2001;36:270-3.
20. Chen TJ, Chou LF, Hwang SJ. Patterns of ambulatory care utilization in Taiwan. BMC Health Services Research. 2006;6:54.
21. Lew-Ting CY. Antibiomedicine belief and integrative health seeking in Taiwan. Social Science & Medicine. 2005;60:2111-6.
22. Lee CH, Chen JJ, Liang WM. Attitudes and intentions of patients toward integrated Chinese and Western medicine In Taiwan. Journal of Alternative & Complementary Medicine. 2006;12:233-6.
23. Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine In Taiwan. BMC Health Services Research. 2007;7:26.
24. Huang YM, Wang HP, Yang YH, et al. Effects of a national health education program on the medication knowledge of the public in Taiwan. Annals of Pharmacotherapy. 2006;40:102-8.
25. Shin FJ. Concepts related to Chinese patients' perceptions of health, illness and person: issues of conceptual clarity. [Review] [26 refs]. Accident & Emergency Nursing. 1996;4:208-15.
26. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Annals of Internal Medicine. 1985;103:1-6.
27. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-54.
28. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE study research group. [see comment]. New England Journal of Medicine. 1991;325:1468-75.
29. Massie BM. 15 years of heart-failure trials: what have we learned? [Review] [33 refs]. Lancet. 1998;352:Suppl-33.
30. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. New England Journal of Medicine. 1986;314:1547-52.
31. Bristow MR. The adrenergic nervous system in heart failure. New England Journal of Medicine. 1984;311:850-1.
32. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circulation Research. 1991;69:1185-95.
33. Bristow MR. The adrenergic nervous system in heart failure. New England Journal of Medicine. 1984;311:850-1.
34. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. [see comment]. New England Journal of Medicine. 1991;325:303-10.
35. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. [see comment] New England Journal of Medicine. 1991;325:293-302.
36. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigattors. [see comment] [erratum appears in N Engl J Med 1992 Dec 10;327(24):1768] New England Journal of Medicine. 1992;327:685-91.
37. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. [see comment] [comment]. Circulation. 1996;94:2807-16.
38. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. [see comment]. New England Journal of Medicine. 1996;334:1349-55.
39. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. [see comment]. Lancet. 2000;355:1575-81.
40. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. [see comment]. New England Journal of Medicine. 1999;341:709-17.
41. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. [Review] [98 refs]. JAMA. 2002;287:883-9.
42. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:E154-E235.
43. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
44. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. [erratum appears in Can J Cardiol. 2006 Mar 1;22(3):271]. [171 refs]. Canadian Journal of Cardiology. 2006;22:23-45.
45. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. [Review] [105 refs]. Journal of Cardiac Failure. 2006;12:10-38.
46. The effect of digoxin on mortality and morbidity in patients with heart failure: the Digitalis Investigation Group. [see comment] New England Journal of Medicine. 1997;336:525-33.
47. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. [see comment]. JAMA. 2003;289:871-8.
48. Adams KF, Jr., Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. [see comment]. J Am Coll Cardiol. 2005;46:497-504.
49. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. [update of Cochrane Database Syst Rev. 2004;(1):CD003178; PMID: 14974008]. [Review] [31 refs]. Cochrane Database of Systematic Reviews. 2005;CD003178.
50. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group New England Journal of Medicine. 1987;316:1429-35.
51. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. [see comment]. Lancet. 2000;355:1582-7.
52. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. [see comment] [summary for patients in J Card Fail. 2002 Apr;8(2):56-8; PMID: 12016625]. New England Journal of Medicine. 2001;345:1667-75.
53. Mcmurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. [see comment]. Lancet. 2003;362:767-71.
54. Granger CB, Mcmurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. [see comment]. Lancet. 2003;362:772-6.
55. Pfeffer MA, Mcmurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. [see comment] [erratum appears in N Engl J Med. 2004 Jan 8;350(2):203]. New England Journal of Medicine. 2003;349:1893-906.
56. Matsumori A, Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. [erratum appears in Eur J Heart Fail. 2004 Jun;6(4):523]. European Journal of Heart Failure. 2003;5:669-77.
57. Effect of metoprolol cr/xl in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) [see comment] Lancet. 1999;353:2001-7.
58. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 2001;38:932-8.
59. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. [see comment] Lancet. 1999;353:9-13.
60. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies - CIBIS And CIBIS II. Cardiac Insufficiency Bisoprolol Study. American Heart Journal. 2002;143:301-7.
61. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. [see comment]. Lancet. 2003;362:7-13.
62. Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999;33:916-23.
63. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. [see comment] [erratum appears In N Engl J Med. 2003 May 29;348(22):2271]. New England Journal of Medicine. 2003;348:1309-21.
64. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. Journal of Cardiac Failure. 1999;5:178-87.
65. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. [see comment] [erratum appears in N Engl J Med. 2005 Mar 24;352(12):1276]. New England Journal of Medicine. 2004;351:2049-57.
66. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. [see comment] [erratum appears in N Engl J Med. 2005 May 19;352(20):2146]. New England Journal of Medicine. 2005;352:225-37.
67. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber And VVI Implantable Defibrillator (DAVID) Trial. [see comment]. JAMA. 2002;288:3115-23.
68. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-7.
69. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. [see comment]. New England Journal of Medicine. 2005;352:1539-49.
70. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. [see comment]. New England Journal of Medicine. 2004;350:2140-50.
71. Singh JP, Ruskin JN. Cardiac resynchronization therapy: the MGH experience. Annals of Noninvasive Electrocardiology. 2005;10:Suppl-54.
72. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart And Lung Transplantation: eighteenth Official Report-2001. The Journal of Heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2001;20:805-15.
73. Trulock EP, Edwards LB, Taylor DO et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart-lung transplant report - 2004. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2004;23:804-15.
74. Hunt SA, Frazier OH. Mechanical circulatory support and cardiac transplantation. [Review] [103 refs]. Circulation. 1998;97:2079-90.
75. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. [see comment] [summary for patients in J Card Fail. 2002 Apr;8(2):59-60; PMID: 12016626]. New England Journal of Medicine. 2001;345:1435-43.
76. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. [comment]. Circulation. 1995;91:2504-7.
77. Douglas PS, Morrow R, Ioli A, et al. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13:311-5.
78. Vasan RS, Larson MG, Benjamin EJ, et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. [see comment]. New England Journal of Medicine. 1997;336:1350-5.
79. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. [see comment]. New England Journal of Medicine. 2006;355:1873-84.
80. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431-9.
81. Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. [see comment]. Journal of Cardiac Failure. 2006;12:327-32.
82. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-44.
83. Cleland JG, Coletta AP, Nikitin NP, et al. Clinical trials update from the American College Of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. European Journal of Heart Failure. 2006;8:326-9.
84. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941-8.
85. Aguilar D, Bozkurt B, Pritchett A, et al. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007;50:32-6.
86. Tang WHW, Maroo A. PPARgamma agonists: safety issues in heart failure. Diabetes, Obesity and Metabolism. 2007;9:447-454.
87. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between hba1c levels and mortality in patients with diabetes and advanced systolic heart failure. American Heart Journal. 2006;151:91.
88. Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. [see comment]. JAMA. 2002;287:1541-7.
89. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. [see comment] [erratum appears in JAMA 2002 Aug 7;288(5):577]. JAMA. 2002;287:1531-40.
90. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. British Heart Journal. 1987;57:17-22.
91. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. American Journal of Cardiology. 2004;93:237-40.
92. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. [see comment]. [Review] [99 refs]. JAMA. 2002;287:628-40.
93. Mcmurray J, Pfeffer MA. New therapeutic options in congestive heart failure: Part II. [Review] [53 refs]. Circulation. 2002;105:2223-8.
94. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA: the journal of the American Medical Association. 2002;287:1531-40.
95. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-91.
96. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA: the journal of the American Medical Association. 2005;293:1900-5.
97. Adams KF, Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal. 2005;149:209-16.
98. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132-43.
99. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. American Journal Of Medicine. 1994;96:191-9.
100. Costanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. [see comment]. J Am Coll Cardiol. 2005;46:2047-51.
101. Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. [Review] [53 refs]. Cardiology. 2001;96:144-54.
102. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. [see comment]. Lancet. 2005;366:2005-11.
103. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190-5.
104. Mcalister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. [see comment]. [Review] [46 refs]. J Am Coll Cardiol. 2004;44:810-9.
105. Fonarow GC. Heart failure disease management programs: not a class effect. [comment]. Circulation. 2004;110:3506-8.
106. Sisk JE, Hebert PL, Horowitz CR, et al. Effects of nurse management on the quality of heart failure care in minority communities: a randomized trial. [summary for patients in Ann Intern Med. 2006 Aug 15;145(4):I28; PMID: 16908913]. Annals of Internal Medicine. 2006;145:273-83.
107. Cleland JG, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. [see comment]. J Am Coll Cardiol. 2005;45:1654-64.
108. Ho YL, Hsu TP, Chen CP, et al. Improved cost-effectiveness for management of chronic heart failure by combined home-based intervention with clinical nursing specialists. Journal of the Formosan Medical Association. 2007;106:313-9.
109. Tsuyuki RT, Mckelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Archives of Internal Medicine. 2001;161:2337-42.
110. Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. [Review] [34 refs]. Reviews in Cardiovascular Medicine. 2002;3:Suppl-S10.
111. Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534-41.
112. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). American Journal of Cardiology. 2001;87:819-22.
113. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation. 2001;103:2768-70.
114. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. American Heart Journal. 2004;148:43-51.
115. Wagoner LE, Starling RC, O'Connor CM. Cardiac Function and Heart Failure. J Am Coll Cardiol. 2006;47:D18-D22.
116. American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. [see comment] [erratum appears in Am J Respir Crit Care Med. 2003 May 15;1451-2]. [Review] [545 refs]. American Journal of Respiratory & Critical Care Medicine. 2003;167:211-77.
117. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. Journal of Applied Physiology. 1986;60:2020-7.
118. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-86.
119. Bard RL, Gillespie BW, Clarke NS, et al. Determining the best ventilatory efficiency measure to predict mortality in patients with heart failure. Journal of Heart & Lung Transplantation. 2006;25:589-95.
120. Coats AJ, Adamopoulos S, Meyer TE, et al. Effects of physical training in chronic heart failure. [see comment]. Lancet. 1990;335:63-6.
121. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. [see comment]. [Review] [108 refs]. American Journal of Medicine. 2004;116:693-706.
122. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTra-MATCH). [see comment]. BMJ. 2004;328:189.
123. Task Force of the Italian Working Group on Cardiac Rehabilitation and Prevention. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation. European Journal of Cardiovascular Prevention & Rehabilitation. 2006;13:10-12.